Although HCV infection mainly induces liver injury, chronic disease is systemic. Moreover, host and viral factors, as well as comorbidities, may influence the chance of achieving a sustained virological response or disease outcome. Although there are sufficient data on the use of peg-interferon and ribavirin in patients with comorbidities, there is very little data on first generation protease inhibitors, which include significant drug-drug interactions and have therefore been administered with caution in these patients. The availability of new, more effective direct acting antivirals should significantly change this scenario. All these issues are discussed in this review.
Keywords: cost/effectiveness; direct acting antivirals; hepatitis C virus; modifiable; non-modifiable comorbidities; sustained viral response.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.